Solcitinib 是一种可口服的，选择性的竞争性JAK1抑制剂，IC50值为 9.8 nM，可用于银屑病的研究。它对其选择性是对 JAK2、JAK3 和 TYK2 的 11、55 和 23 倍。

Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.

In vitro HotSpotSM kinase profiling of 289 kinases is performed. The assay is conducted in the presence of 10 μM [33P]-ATP, using brigatinib concentrations ranging from 0.05 nM to 1 μM.

1206163-45-2

C22H23N5O2

389.45

索西替尼;GSK-2586184;GLPG-0778

DMSO:20 mg/mL(51.4 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years